#LungCancer #NonSmallCellLungCancer #CancerResearch With the new cobas Epidermal Growth Factor Receptor test, doctors at some public hospitals are now able to detect the presence of gene mutations. About half of non-small cell lung cancer is linked to a genetic epidermal growth factor receptor (EGFR) mutation - affecting mostly female non-smokers.
Erbitux is for head and neck cancer as well as metastasized colon cancer. It works by inhibiting the EGFR receptor, a growth factor receptor in the epidermal tissues. This keeps the cancerous cells from growing.
Thousands of women with breast cancer could be spared chemotherapy following NHS approval of a test which can help establish who needs the treatment and who might not...the oncotype DX test, was approved for women who have oestrogen receptor positive (ER+), lymph node negative (LN–) and human epidermal growth factor receptor 2 negative (HER2–) in early breast cancer..
EGFR stains using the DakoCtomation kit on colon carcinomas. Nonspecific cytoplasmic staining (left) is common, and should be ignored. - http://www.propath.com/companies/press-clippings/26-newsletters/267-epidermal-growth-factor-receptor-and-erbitux-march-2004
Iressa is the international trade name for Gefitinib 250mg tablets that is manufactured by Astrazeneca Pharmaceuticals. Gefitinib 250 mg Iressa belongs to a class of anti-cancer medications called Epidermal Growth Factor Receptor (EGFR) tyrosine kinaseinhibitors. Get Iressa Price which medicine used for the treatment of non-small cell lung cancer. By keeping track with the latest market development, Anti Cancer Aid introducing high quality of Pha
Nov 2015- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.